U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07706088) titled 'Effect of Tirzepatide on Diabetic Peripheral Sensorimotor Neuropathy' on July 10.
Brief Summary: Tirzepatide is a dual agonist of GLP-1 Receptor and the GIP receptor, producing substantial improvement in glycaemic control, weight reduction and insulin sensitivity. Beyond its metabolic effects, incretin signalling has demonstrated neuroprotective and neurotropic properties, including activation of intracellular pathways that enhance neuronal survival and regeneration.
Using tirzapatide for diabetic sensorimotor peripheral neuropathy and assessing with CCM / NCS and BDNF will represent three complementary aspects of nerve regeneratio...